MOLyF : Bone Marrow and Follicular Lymphoma

NCT ID: NCT06608147

Last Updated: 2024-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-04

Study Completion Date

2034-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from control subjects.

Follicular lymphoma is the most common indolent lymphoma. It is characterised by systematic relapses and bone marrow dissemination in 70% of patients at the time of diagnosis.

Although relapses are thought to be related to refractory tumour cells nested in a supportive microenvironment in the bone marrow, the mechanisms involved are poorly understood.

To study the specificities of the bone marrow of patients with follicular lymphoma, It is necessary to compare them with control samples.

This study takes advantage of surgeries involving sternotomies to recover lost bone marrow and establish a bone marrow bank of patients without hematological disease.

This bank will be used to set up control cohorts for other clinical trials involving patients with follicular lymphoma.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, Follicular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Group Type EXPERIMENTAL

Sampling

Intervention Type OTHER

sternal bone marrow aspiration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sampling

sternal bone marrow aspiration

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major patient
* Patient hospitalized in the thoracic, cardiac and vascular surgery department for surgery involving a sternotomy
* Patient with free, informed, written consent
* Patient covered by a health insurance scheme

Exclusion Criteria

* History of haematological malignancy or haemogram disturbance
* Immunomodulating treatment: immunosuppressants, corticoids, antineoplastics
* Persons covered by articles L. 1121-5 to L. 1121-8 and L. 1122-1-2 of the French Public Health Code (e.g. minors, protected adults, etc.)\].
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Rennes University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Juliette Ferrant, MD

Role: STUDY_CHAIR

CHU Rennes

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Rennes

Rennes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Juliette Ferrant, MD

Role: CONTACT

Phone: 0299282555

Email: [email protected]

Alexandra Guerrier

Role: CONTACT

Phone: 0299282555

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Juliette Ferrant, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

35RC24_9716_MOLyF

Identifier Type: -

Identifier Source: org_study_id